[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626465":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":73,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study arm","EXPERIMENTAL","In general in Erasmus Medical Centre, two applications are applied with an interval of one week for the HDR IGABT. Patients will be treated with a commercially available applicator (conform the current clinical practice) at week 1 and with the patient-tailored ARCHITECT applicator (study intervention) at week 2.",[13],"Device: ARCHITECT applicator",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","ARCHITECT applicator","Patient-tailored, 3D-printed applicator",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"H. Westerveld, MD, PhD","CONTACT","+31 10 704 1249","g.westerveld@erasmusmc.nl",[28],{"facility":5,"status":20,"city":29,"state":20,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Rotterdam","3015 GD","Netherlands","NL",{"type":34,"coordinates":35},"Point",[36,37],4.47917,51.9225,{"lat":37,"lon":36},[40,41,43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":23,"role":42,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"name":44,"role":45,"phone":20,"phoneExt":20,"email":20},"A. Corbeau, MSc","SUB_INVESTIGATOR",{"type":42,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Dr. G.H. (Henrike) Westerveld","Radiation oncologist","100626465","clinical-feasibility-of-the-architect-applicator-in-cervical-cancer-brachytherapy-100626465",false,"NCT07435987","Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy","Clinical Feasibility of the ARCHITECT Applicator in High-dose-rate Cervical Cancer Brachytherapy","ARCHITECT","Inclusion Criteria:\n\n* Locally advanced cervical cancer (FIGO 2018 stage 1B3-IVA) with indication for primary radiotherapy including brachytherapy\n* Written informed consent\n\nExclusion Criteria:\n\n* Unable to give informed consent;\n* Tumour extension in the lower 2\u002F3rd of the vagina;\n* Requiring a Geneva tandem with ovoids' size 13 mm in the first application for brachytherapy;\n* Known nylon allergy.","FEMALE","18 Years",{"count":60,"type":61},25,"ESTIMATED","INTERVENTIONAL",[64],"NA","This prospective, non-randomised, single centre, phase I trial assesses the clinical feasibility of the use of the patient-tailored ARCHITECT applicator in locally advanced cervical cancer brachytherapy.",[67,68],"Locally Advanced Cervical Cancer","Uterine Carcinoma",[70,71,72],"Brachytherapy","Patient-tailored applicator","3D-printed applicator","NOT_YET_RECRUITING","2026-02-20",{"date":76,"type":77},"2026-02-27","ACTUAL",{"date":79,"type":61},"2026-05",{"date":81,"type":61},"2027-12",{"name":5,"class":6},1]